How to Give Allergy Injections: Advanced Protocols & Dose Adjustment

After a systemic reaction to an allergy shot (any WAO grade from 1 to 4), the supervising allergist must review the case before the next injection is administered. Generally, the next dose is reduced to the last well-tolerated dose — meaning the highest dose that did not cause a reaction. Re-escalation then proceeds at a more conservative rate, typically half the standard dose increment per visit rather than the full increment. The specific adjustment protocol should be prescribed by the allergist and documented in the patient's chart before the next visit. In some cases, particularly after Grade 3-4 reactions, a full clinical reassessment including spirometry for asthmatic patients may be warranted before resuming immunotherapy. The goal is to re-establish tolerance at the lower dose before carefully advancing again.

If a patient needs to pause allergy shot treatment for any reason — travel, illness, insurance lapse, pregnancy — the critical variable is how long the pause will be. Short pauses (1-4 weeks during build-up) typically require only one dose level reduction. Extended pauses (more than 8 weeks during build-up) may require returning to a substantially lower dose. The allergist should be contacted before the patient resumes treatment after any significant gap. Once restarted, documentation should note the date of the last injection, the reason for the pause, and the allergist's prescribed dose for resumption. Patients in the maintenance phase tolerate pauses better than those in build-up, with some able to resume their maintenance dose after 6-8 weeks without a reduction — but this should always be confirmed with the prescribing allergist.

When a patient receives injections from more than one allergen vial per visit, each injection should be given at a separate site with at least 2 cm of separation between injection points. Separate sites allow each injection to be monitored independently for local reaction and prevent the different extract concentrations from intermixing in the subcutaneous tissue. A waiting period of 15-30 minutes between injections from different vials is recommended to allow early systemic signs to emerge before the next allergen challenge. Documentation should record which vial was given at each specific site. If a reaction occurs between vials, the subsequent vials should not be administered — contact the allergist immediately. The total observation period runs from the last injection given.

Pregnancy does not require stopping allergen immunotherapy for patients who are already on a stable maintenance dose with no history of systemic reactions. The AAAAI practice parameters allow continuation of maintenance SCIT during pregnancy because the risk of reaction is low at the established dose and the benefit of continued allergen tolerance may reduce pregnancy-related allergy complications. However, the dose should not be escalated during pregnancy because increasing doses carry a higher reaction risk, and anaphylaxis treatment (including epinephrine) during pregnancy carries fetal risk. SCIT should not be initiated in a pregnant patient — starting a new immunotherapy program introduces escalating dose risks that are inappropriate during pregnancy. Always consult the supervising allergist before any dose modification in a pregnant immunotherapy patient.

Cluster immunotherapy is an accelerated build-up protocol in which a patient receives 2 to 3 injections at progressively increasing doses during a single clinic visit, repeated over several weeks until the maintenance dose is reached. Unlike conventional weekly build-up (which takes 3-6 months), cluster protocols compress the build-up phase to approximately 6-8 weeks, reaching maintenance much sooner. The clinical tradeoff is a higher immediate visit burden — each cluster session takes 60-90 minutes or longer due to the multiple injections and extended post-injection observation. Cluster protocols are appropriate for selected patients with good access, no high-risk history, and a clinical need for faster build-up. Tversky (2022) reviewed cluster immunotherapy safety and found it achieves maintenance faster with a somewhat higher (but manageable) local and systemic reaction rate compared to conventional build-up.

Children receiving allergen immunotherapy generally follow the same extract formulation and build-up schedule as adults, but several technique modifications are appropriate for pediatric patients. Younger children — particularly those under 8 — may require distraction techniques during injection to minimize anticipatory anxiety and reduce vasovagal risk. Effective approaches include age-appropriate distraction (bubble-blowing, tablet games, caregiver narration) and gentle positive reinforcement. Some allergists prescribe slightly lower injection volumes for very young or small children. The observation period is the same 30 minutes required for all patients. Involving the caregiver in pre-injection preparation and post-injection comfort is important. Studies show that children who receive regular allergy shots during childhood may have reduced risk of developing new allergen sensitivities and progression from allergic rhinitis to asthma.